Figure 1. Position of respondents regarding a delayed disclosure of five essential protocol items n= 261

- No delayed disclosure: 56%
- Undecided: 13%
- Acceptable upon trial completion: 19%
- Acceptable upon regulatory approval: 7%
- Acceptable during the trial: 5%
- Acceptable when commercial products is first marketed: 1%